Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus gemcitabine/cisplatin bladder-preservation study after maximal TURBT in MIBC
ChiCTR2200067146Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Dec 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, gemcitabine and cisplatin in bladder cancer and transitional cell carcinoma (TCC), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Clinical complete response rate. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
tislelizumabgemcitabinecisplatin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2200067146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067146.